Limits...
A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients.

Patel N, Nasiri M, Koroglu A, Bliss S, Davis M, McNutt LA, Miller C - Infect Dis Ther (2015)

Bottom Line: Similarly, use of ≥6 home medications was also the only variable associated with an increased probability of XDDI involving SOF-containing therapy (OR 3.83, 95% CI 2.57-5.70, p < 0.001).Sofosbuvir-containing therapy had a lower frequency of XDDIs than SIM-containing therapy.Polypharmacy with various classes of home medications predicted XDDIs involving SIM- or SOF-containing therapy.

View Article: PubMed Central - PubMed

Affiliation: Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, NY, 12208, USA, nimish.patel@acphs.edu.

ABSTRACT

Introduction: This study compares the expected occurrence of contraindicated drug-drug interactions (XDDIs) when simeprevir (SIM)- or sofosbuvir (SOF)-containing therapy is added to medication profiles of patients with hepatitis C (HCV) monoinfection to quantify, in relative terms, the population-based risk of XDDIs. Second, this study identified the predictors of XDDIs when HCV therapies are added to medication profiles.

Methods: A cross-sectional study was performed among Veterans' Affairs patients. Inclusion criteria were: (1) age ≥18 years, (2) HCV infection, and (3) availability of a medication list. Patients with human immunodeficiency virus were excluded. Demographics, comorbidities, year of HCV diagnosis, and most recent medication list were collected from medical records. The primary outcome was the presence of XDDIs involving HCV therapy and the medications in the patient's home medication list after the addition of either SIM- or SOF-containing regimens. To define XDDIs, Lexi-Interact drug interaction software was used.

Results: 4,251 patients were included. The prevalence of XDDIs involving SIM- or SOF-containing therapy were 12.6% and 4.7% (p < 0.001), respectively. In multivariable analyses examining the predictors of XDDIs involving SIM-containing therapy, the only medication-related predictor was use of ≥6 home medications (odds ratio OR 4.58, 95% confidence interval CI 3.54-5.20, p < 0.001). Similarly, use of ≥6 home medications was also the only variable associated with an increased probability of XDDI involving SOF-containing therapy (OR 3.83, 95% CI 2.57-5.70, p < 0.001).

Conclusions: Sofosbuvir-containing therapy had a lower frequency of XDDIs than SIM-containing therapy. Polypharmacy with various classes of home medications predicted XDDIs involving SIM- or SOF-containing therapy.

No MeSH data available.


Related in: MedlinePlus

Prevalence of contraindicated drug–drug interactions (XDDI) involving hepatitis C therapy after addition of simeprevir- and sofosbuvir-containing therapy
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4363220&req=5

Fig1: Prevalence of contraindicated drug–drug interactions (XDDI) involving hepatitis C therapy after addition of simeprevir- and sofosbuvir-containing therapy

Mentions: The prevalence of XDDI before the addition of SIM- or SOF-containing therapy was 16.7% (n = 709). After the addition of SIM- and SOF-containing therapy, the overall prevalence of XDDIs significantly increased to 25.9% (n = 1,103) and 19.9% (n = 844, p < 0.001), respectively. When restricting interactions to only those involving SIM- or SOF-containing therapy (Fig. 1), the prevalence of XDDIs after the addition of these drugs was 12.6% (n = 535) and 4.7% (n = 201, p < 0.001) for SIM- and SOF-containing therapies, respectively. Upon stratification by the CART-derived breakpoints (< or ≥6 home medications and having < or ≥10 comorbidities), there were significant differences in the frequency of XDDIs involving HCV therapy between SIM- and SOF-containing regimens. The differences within each of the strata were consistent with the overall comparison in that SIM-containing drugs tended to be associated with a greater likelihood of an XDDI.Fig. 1


A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients.

Patel N, Nasiri M, Koroglu A, Bliss S, Davis M, McNutt LA, Miller C - Infect Dis Ther (2015)

Prevalence of contraindicated drug–drug interactions (XDDI) involving hepatitis C therapy after addition of simeprevir- and sofosbuvir-containing therapy
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4363220&req=5

Fig1: Prevalence of contraindicated drug–drug interactions (XDDI) involving hepatitis C therapy after addition of simeprevir- and sofosbuvir-containing therapy
Mentions: The prevalence of XDDI before the addition of SIM- or SOF-containing therapy was 16.7% (n = 709). After the addition of SIM- and SOF-containing therapy, the overall prevalence of XDDIs significantly increased to 25.9% (n = 1,103) and 19.9% (n = 844, p < 0.001), respectively. When restricting interactions to only those involving SIM- or SOF-containing therapy (Fig. 1), the prevalence of XDDIs after the addition of these drugs was 12.6% (n = 535) and 4.7% (n = 201, p < 0.001) for SIM- and SOF-containing therapies, respectively. Upon stratification by the CART-derived breakpoints (< or ≥6 home medications and having < or ≥10 comorbidities), there were significant differences in the frequency of XDDIs involving HCV therapy between SIM- and SOF-containing regimens. The differences within each of the strata were consistent with the overall comparison in that SIM-containing drugs tended to be associated with a greater likelihood of an XDDI.Fig. 1

Bottom Line: Similarly, use of ≥6 home medications was also the only variable associated with an increased probability of XDDI involving SOF-containing therapy (OR 3.83, 95% CI 2.57-5.70, p < 0.001).Sofosbuvir-containing therapy had a lower frequency of XDDIs than SIM-containing therapy.Polypharmacy with various classes of home medications predicted XDDIs involving SIM- or SOF-containing therapy.

View Article: PubMed Central - PubMed

Affiliation: Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, NY, 12208, USA, nimish.patel@acphs.edu.

ABSTRACT

Introduction: This study compares the expected occurrence of contraindicated drug-drug interactions (XDDIs) when simeprevir (SIM)- or sofosbuvir (SOF)-containing therapy is added to medication profiles of patients with hepatitis C (HCV) monoinfection to quantify, in relative terms, the population-based risk of XDDIs. Second, this study identified the predictors of XDDIs when HCV therapies are added to medication profiles.

Methods: A cross-sectional study was performed among Veterans' Affairs patients. Inclusion criteria were: (1) age ≥18 years, (2) HCV infection, and (3) availability of a medication list. Patients with human immunodeficiency virus were excluded. Demographics, comorbidities, year of HCV diagnosis, and most recent medication list were collected from medical records. The primary outcome was the presence of XDDIs involving HCV therapy and the medications in the patient's home medication list after the addition of either SIM- or SOF-containing regimens. To define XDDIs, Lexi-Interact drug interaction software was used.

Results: 4,251 patients were included. The prevalence of XDDIs involving SIM- or SOF-containing therapy were 12.6% and 4.7% (p < 0.001), respectively. In multivariable analyses examining the predictors of XDDIs involving SIM-containing therapy, the only medication-related predictor was use of ≥6 home medications (odds ratio OR 4.58, 95% confidence interval CI 3.54-5.20, p < 0.001). Similarly, use of ≥6 home medications was also the only variable associated with an increased probability of XDDI involving SOF-containing therapy (OR 3.83, 95% CI 2.57-5.70, p < 0.001).

Conclusions: Sofosbuvir-containing therapy had a lower frequency of XDDIs than SIM-containing therapy. Polypharmacy with various classes of home medications predicted XDDIs involving SIM- or SOF-containing therapy.

No MeSH data available.


Related in: MedlinePlus